Abstract
Dermatomycoses are among the most widespread and common superficial and cutaneous fungal infections in humans. These typically nonfatal conditions are difficult to treat, especially infections of the nail. Dermatomycoses are caused by filamentous fungi such as Trichophyton, Microsporum or Epidermophyton species. These filamentous fungi have a high affinity for keratin, an important component of hair, skin and nails, which are the primary areas of infection by dermatophytes. The antifungal agents currently marketed for dermatomycoses are mainly inhibitors of ergosterol biosynthesis, except for griseofulvin, which interferes with the cytoplasmic and nuclear microtubular system. Three different types of inhibitors of the ergosterol biosynthetic pathway have been proven to be effective in clinic: the azoles (e.g. topical miconazole and topical/oral ketoconazole, itraconazole and fluconazole), the allylamines (e.g. terbinafine) and morpholines (amorolfine). Even today more effective antifungal azoles with less adverse effects and short-term therapy are deemed necessary to treat dermatophytosis. A promising novel triazole compound in this respect is R126638, which showed potent in vitro and in vivo activity.
Keywords: dermatomycoses, dermatophytes, yeasts, antifungals, skin kinetics, prevention, resistance, pulse therapy
Current Drug Targets
Title: Fungal Infections of the Skin: Infection Process and Antimycotic Therapy
Volume: 6 Issue: 8
Author(s): M. Borgers, H. Degreef and G. Cauwenbergh
Affiliation:
Keywords: dermatomycoses, dermatophytes, yeasts, antifungals, skin kinetics, prevention, resistance, pulse therapy
Abstract: Dermatomycoses are among the most widespread and common superficial and cutaneous fungal infections in humans. These typically nonfatal conditions are difficult to treat, especially infections of the nail. Dermatomycoses are caused by filamentous fungi such as Trichophyton, Microsporum or Epidermophyton species. These filamentous fungi have a high affinity for keratin, an important component of hair, skin and nails, which are the primary areas of infection by dermatophytes. The antifungal agents currently marketed for dermatomycoses are mainly inhibitors of ergosterol biosynthesis, except for griseofulvin, which interferes with the cytoplasmic and nuclear microtubular system. Three different types of inhibitors of the ergosterol biosynthetic pathway have been proven to be effective in clinic: the azoles (e.g. topical miconazole and topical/oral ketoconazole, itraconazole and fluconazole), the allylamines (e.g. terbinafine) and morpholines (amorolfine). Even today more effective antifungal azoles with less adverse effects and short-term therapy are deemed necessary to treat dermatophytosis. A promising novel triazole compound in this respect is R126638, which showed potent in vitro and in vivo activity.
Export Options
About this article
Cite this article as:
Borgers M., Degreef H. and Cauwenbergh G., Fungal Infections of the Skin: Infection Process and Antimycotic Therapy, Current Drug Targets 2005; 6 (8) . https://dx.doi.org/10.2174/138945005774912726
DOI https://dx.doi.org/10.2174/138945005774912726 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry microRNAs in the Regulation of Adipogenesis and Obesity
Current Molecular Medicine Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia
Current Topics in Medicinal Chemistry Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design PLA2G6 Mutations and Other Rare Causes of Neurodegeneration with Brain Iron Accumulation
Current Drug Targets Urate Transport: Regulators of Serum Urate Levels in Humans
Current Rheumatology Reviews In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Double-crosser of the Immune System: Macrophages in Tumor Progression and Metastasis
Current Immunology Reviews (Discontinued) Nuclear Factor Erythroid 2 - Related Factor 2 Signaling in Parkinson Disease: A Promising Multi Therapeutic Target Against Oxidative Stress, Neuroinflammation and Cell Death
CNS & Neurological Disorders - Drug Targets Identifying Endogenous Neural Stem Cells in the Adult Brain In Vitro and In Vivo: Novel Approaches
Current Pharmaceutical Design Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Hepatitis C Virus Infection
Current Stem Cell Research & Therapy CD48 as a Novel Target in Asthma Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Letter to the Editor: The Versatility of Tumor Suppressor Proteins and its Therapeutic Potential
Protein & Peptide Letters Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Dehydroepiandrosterone in Therapy of Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery